EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. reported a net loss of $232.0 million for fiscal year 2025, driven by a significant loss from operations of $243.4 million. Total revenues were $31.4 million, derived entirely from product sales, license and collaboration agreements, and royalty income. Operating expenses totaled $274.8 million, with research and development costs of $221.0 million being the primary expense. The company ended the year with total assets of $364.0 million, including $101.8 million in cash and cash equivalents and $204.3 million in marketable securities. Total liabilities were $57.9 million, resulting in stockholders' equity of $306.1 million. Cash used in operating activities was $240.1 million, while net cash provided by financing activities was $173.6 million, primarily from stock issuance. The company acknowledges it has incurred significant losses and will likely need additional capital to fund operations.

Key Takeaways